174 related articles for article (PubMed ID: 21183396)
21. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
[TBL] [Abstract][Full Text] [Related]
22. Helicase-primase as a target of new therapies for herpes simplex virus infections.
James SH; Larson KB; Acosta EP; Prichard MN
Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
[TBL] [Abstract][Full Text] [Related]
23. UL52 primase interactions in the herpes simplex virus 1 helicase-primase are affected by antiviral compounds and mutations causing drug resistance.
Muylaert I; Zhao Z; Elias P
J Biol Chem; 2014 Nov; 289(47):32583-92. PubMed ID: 25278021
[TBL] [Abstract][Full Text] [Related]
24. The helicase-primase complex as a target for effective herpesvirus antivirals.
Field HJ; Mickleburgh I
Adv Exp Med Biol; 2013; 767():145-59. PubMed ID: 23161010
[TBL] [Abstract][Full Text] [Related]
25. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
Shiraki K; Yasumoto S; Toyama N; Fukuda H
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
[TBL] [Abstract][Full Text] [Related]
26. New anti-HSV therapeutics target the helicase-primase complex.
Crumpacker CS; Schaffer PA
Nat Med; 2002 Apr; 8(4):327-8. PubMed ID: 11927930
[No Abstract] [Full Text] [Related]
27. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1.
Biswas S; Smith C; Field HJ
J Antimicrob Chemother; 2007 Aug; 60(2):274-9. PubMed ID: 17550887
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
Katsumata K; Chono K; Kato K; Ohtsu Y; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2013 Mar; 57(3):1339-46. PubMed ID: 23274658
[TBL] [Abstract][Full Text] [Related]
29. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
30. A short commentary on the review by Weller and Kuchta: the DNA helicase-primase complex as a target for herpes virus infection.
Field HJ
Expert Opin Ther Targets; 2013 Oct; 17(10):1113-4. PubMed ID: 24044544
[No Abstract] [Full Text] [Related]
31. Drugs in development for herpes simplex and varicella zoster virus.
Birkmann A; Zimmermann H
Clin Pharmacol Ther; 2017 Jul; 102(1):30-32. PubMed ID: 28160282
[TBL] [Abstract][Full Text] [Related]
32. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor.
Sukla S; Biswas S; Birkmann A; Lischka P; Zimmermann H; Field HJ
J Antimicrob Chemother; 2010 Jul; 65(7):1347-52. PubMed ID: 20453068
[TBL] [Abstract][Full Text] [Related]
33. The DNA helicase-primase complex as a target for herpes viral infection.
Weller SK; Kuchta RD
Expert Opin Ther Targets; 2013 Oct; 17(10):1119-32. PubMed ID: 23930666
[TBL] [Abstract][Full Text] [Related]
34. 1,2,4-Triazoloazine derivatives as a new type of herpes simplex virus inhibitors.
Deev SL; Yasko MV; Karpenko IL; Korovina AN; Khandazhinskaya AL; Andronova VL; Galegov GA; Shestakova TS; Ulomskii EN; Rusinov VL; Chupakhin ON; Kukhanova MK
Bioorg Chem; 2010 Dec; 38(6):265-70. PubMed ID: 20947122
[TBL] [Abstract][Full Text] [Related]
35. Ribonucleotide reductase inhibitors as anti-herpes agents.
Wnuk SF; Robins MJ
Antiviral Res; 2006 Sep; 71(2-3):122-6. PubMed ID: 16621038
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo.
Himaki T; Masui Y; Chono K; Daikoku T; Takemoto M; Haixia B; Okuda T; Suzuki H; Shiraki K
Antiviral Res; 2012 Feb; 93(2):301-304. PubMed ID: 22155691
[TBL] [Abstract][Full Text] [Related]
37. Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo.
Hou J; Zhang Z; Huang Q; Yan J; Zhang X; Yu X; Tan G; Zheng C; Xu F; He S
BMC Infect Dis; 2017 Mar; 17(1):217. PubMed ID: 28320320
[TBL] [Abstract][Full Text] [Related]
38. 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
Schnute ME; Cudahy MM; Brideau RJ; Homa FL; Hopkins TA; Knechtel ML; Oien NL; Pitts TW; Poorman RA; Wathen MW; Wieber JL
J Med Chem; 2005 Sep; 48(18):5794-804. PubMed ID: 16134946
[TBL] [Abstract][Full Text] [Related]
39. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
Biswas S; Swift M; Field HJ
Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
[TBL] [Abstract][Full Text] [Related]
40. [Complex of the herpes simplex virus initiator protein UL9 with DNA as a platform for the design of a new type of antiviral drugs].
Surovaia AN; Gorohovskiĭ SL; Gurskiĭ IaG; Andronova VL; Arkhipova VS; Bazhulina NP; Galegov GA; Gurskiĭ GV
Biofizika; 2010; 55(2):239-51. PubMed ID: 20429277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
